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Milrinone is an orally active phosphodiesterase inhibitor that 
ha8 been shown to improve xercise capacity in patient8 
with moderate conge8tive h art failm (l-6). Although this 
action might be of clinical value, the results of the PROMISE 
trial (7), a large randomized study of the e&t of oml 
mihinone on survival in patient8 with severe congestive 
heart failure, have demonstrated that long-term administra- 
tion of milrinone in the doses given is associated with an 
increase inmortality. The results of the PROMISE trial have 
had a major impact on the development oforal milrinone and 
may be relevant to several other new agents with phosphod- 
iesterase inhibiting activity. 
Coincident with the PROMISE trial, two other placebo- 
controlled multicenter trials, referred to as MIL-1077 and 
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ML1078, were conducted to evaluate the clinical ellicacy 
of oral milrinone when used in combimtion with convertiag 
enzyme inhibitors in patients with moderate congestive h art 
faihne. we considered it important to evaluate mihinone in 
patients receiving converting enzyme inhibii because 
patient8 receiving converting enzyme inhiitors were ex- 
cluded from the study by DiBianco et al. (6), the only 
previously published controlled trial of the &ect of oral 
milrinone on exercise capacity. The study by DiBiico et al. 
(6) also found that milrinone used in combination with 
digitalis cau8ed no fiuther increase inexerci8e capacity and 
thereby raised the possibility hat digitalis might attenuate 
the milrinone-induced improvement i  exercise. Therefore. 
one of the trials (MlLlU77) examined the ekacy of milri- 
none in patient8 receiving a converting enzyme h&iXtor but 
not digitalis, and the other (MlL-1078) examined the effects 
ofmilrhmne in patients receiving both a coavertiw enzyme 
inhibitor and digitalis. 
EOth bial8 were terminated prematurely in October 1990 
when the results of the PROMlSE trial were released 0). At 
tbattime,atatalof254patientshadbeen~~~~o 
twotrialsandatotalofl~patient8hadcompletedthe~8 
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meritair. w~theexceptionoftheuseuf~s, 
~ensry~fmhmrostudiiweresimilar.Menand 
~~)8yearrrofalpewereeti#iitef~bOthStUdieS.~ 
p&&dUldtObVCNCWYdHWUtASSOCiatiOUfunctiopnal 
classIIOrI.IIS~nfmawetOCUIlgeStiWhearz~~ 
withaleftveatriculorejaetioprfraCtiWs4WbbYnuclear 
~ntricul0gitph~~ III both studies, did agents must have 
beenused~r8daysbefohe~pbaseeatry.The~5e 
d @it&~ was prdibitcd in MIGlO77 but required in 
hiIL-1978. InluILlU78, patients must have been receivin8 
digouin~rz8daysbeforuentryhWhebaselhrepbase.The 
converting enzyme inhibitors inboth studii consisW of 
capu#l (lnbumal dose 12.5 lng twice daily) and ena@ril 
(mbdmaldose5m8twicedaily).Patientsmustbavebeen 
lH&iflgCOflV~enZymeiUhibi~forr2monthsbe- 
trweelltryintothebaselinephaseofcithcrstudy. 
Exchuii uitcria included the use of other Msodiletors, 
~an&@!us,calciumchanuelbloclrenr,an8ina- 
limitedexercise,myuca&ali&ctkmwithin3monthsof 
baseliEstudy,coll9estiveheart~duetoobstNcuve 
valvulsrheartdiHu!?e,hypertFopbicorre!?tMvecmdio- 
myoyat&tbyroid ,myocauWormamm&m&ar- 
ti6Cid~VtllW.patiwtsWith~S~pulfUO- 
muy~orprimarylivcroed~wereexcluded. 
IWllts~vingantiarrbytbmic~wUeiacbrdedaSlong 
asthedailydoseofantianhythmicnledk&mhadbeenstable 
forr7daysforallautisnhythmica9entswithtbe~of 
. 
armodarone,forwhichastabledosewasrequindfor4numths. 
orenc&ide,lbrwbichastabledosewasrequkedfor3Odeys. 
Patiems~d@ymmW!andliecaiWwere-In 
bothstudb&22%dtlEpath#&weMXeivhql~ 
~.Mientswithapriorhistoryofven&&riibrill&nor 
suddeacmdiEdeathweluexch&d. 
mphrr. Fatientsmeetin9entrycrheriawereseen 
in~clilricatl,3,5,7arpd9wsdrsrftertheinitialvisitto 
establish clinical stability and the reproducibility ofexetcise 
perfibPmance.AllpstientsMowulupwereinthebaselii 
phssefor~Sweeks.Thedosesofdi8oxin,diureticagentand 
convertingenuymeinhWtorcouklbemodiHasclinically 
htdicateddurinSthebasehneperiod.However,thelerq@of 
theba8elineperiodbadtobeextendedsotbatconstantdaily 
dosesofdigoxinanddiicagenthadbeenmsintainedfor 
22 weeks and a constant dose ofconvertin8 enzyme inhii 
itorhadbeenmainudWtbrdweeksb&e~ 
tion.Ifthesecriteriawerenotmetwithin9weeks,patients 
werenotel@ibleforrando&athm.Ailpatieats~veda 
placebo caplet, identicsl in~toalO-mgmihhmne 
caplet, four timedday durin8 the baseline phase. The inves- 
tieatorbutnotthepatientwasawarethatthemedicationwas 
placebo. 
mbk 1. Fmanitythmiactiteria* 
Easch Follow-Up 
vpc m=Yh 4 a10 
MO 210 x baseline 
51-100 2s x basebe 
101-300 ZAXbdiW 
all 23 X basclhc 
ltcp&kpDiraum 51 210 
>l r10xbasck 
vaarieuhrhcbycardia <5 MO 
mJb) a5 10xbas&c,orwrtrhKdVTNF 
~ihmtkcriterhd~~ad.(Q).VPC=vemiahr 
pemrtw complcm; WWF = ventricular tachycardiahre nniwlsr mih- 
tion. 
Enrcrdsc~~ The@uaryendpointofboth 
clinicsl trials was exercise duration on a modified Naugbton 
protowl(8). To be el@ble for this study, patients bad to 
exercise for r2 min but not >16 min. The exercise t st was 
pe&med at Zweek intervals during the baseline phase. It
wastequiredthattheexercisedurationdiErby ~Zminover 
conseMive tests to enter the randomizaton phase. 
. 
I&&M&IL Fatientswholidiilledalltheuiteriadur- 
iog the baseline phafie (as just defmed) were randomized to 
therapy with mihinone or an iderHical+ppesring placebo 
aplet. The h&al dose regimen for milrinone was 10 mg four 
timesdaily,withtbeoptionofa@stin8tbedoseupwardor 
downward according tothe judgment of the investigator. 
‘Ihemaximalalloweddsilydoseofmilrinonewus6Omg.The 
a~dailydosesofmiirinonewere34~ ImginMIL 
1077 nd34=1mginIuIL-1078. 
rmWMmllu&kuma @mu. The two trials di&ud 
in duration; MU&I77 lasted 6 months, whereas ML-1078 
was3monthsinduratiou.Inbothtrials.patientswereseen 
forchnicalevaluationatweeksland2andmonthlythere- 
sfter.Inbothhials,exer&e t stingandaqualityoflife 
assessmentwereperformedatweek2andmonthlythere- 
after. 
AmbuhterydeetroclrdiDgrqpbicmenWug. A24-ham- 
b&tory Holter elec~phic recording Jvas made 
duringweek3ofthebaselinephaseandattheendofweek 
1 and month 1ofthe maintenance placebo4xWrolled phsse. 
Th recordswereanal~withregudtothefrequencyof 
ventricular p emature complexes, repetitive ventricular 
forms and ventricular tachycardii Folhnv-up recordings 
were~withtbebaselinerocoulingandanalyzedfor 
proarrhythmiabyamodhWhmofthecrheriaproposedby 
Mor9anroth et al. (9) Vable 1). In addition, recou@s were 
anslyzedtodetern&wbetberthelenqtbofthelon8estrun 
of v tric&u tachycardia increased (10). 
AItaly& Alldataau?pxusentedasthemeanval~~ 1 
SIX The analysis of e6Icacy presented is fir the 140 
~~~whowmpletedthetrialsanddoesnotretledthell4 
p ie tswhohadnotreachedanendpointwhentbetrials 
wereterminaUAttbetimethetwostudiesweretenni- 
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Tabk 2. Baseline Characteristics of Patients Who Reached a 
Study End Point in MIL1077 and ML-1078 
MILIo77 YIL-1078 
- 
FlacebD Yilrime RXlW Milrinone 
(n = 25) (n = 311 (n -38) (n=IJ 
lrse (Yr) 6023 6023 6023 6623 
MeleO 88 81 76 78 
NYHA class (46) 
II 56 74 45 48 
III 44 26 50 50 
IV 0 0 5 
LVEF (%) 2523 2623 2423 zsf3 
Etido&y of heati 
failure 1%) 
76 55 42 46 
DCY 24 45 58 54 
Other 4 3 16 20 
VduCs LIZ prasaated as mean value f I SEM or percent. CAD = 
coronary artery disease; DCM = dilated cardiomyopathy: LVEF = left 
~ntri~ul~r #cth !hcticm ML4077 = trial of mitrinonc plus a convutillg 
enzyme inhibitor wifhrr digitalis: MIL4078 =trial of milrinone plus a 
cooverting enzyme iahibitor wirh digitalis; NYHA class = New York Heart 
A!xowoa flmctional class. 
nati, 140 of the 254 randomized patients had completed the 
entire duration of one or the other trial (3 months for 
MILlO78 or 6 months for MILlU77) or they were with- 
drawn from one of the studies because of a serious adverse 
event, the need for therapeutic cointervention r death. 
Results 
htht clwmW&s (Table 2). The characteristics of 
the two study groups WZie similar with minor exceptions. Of
the patients who completed MILlO77, the Mority were in 
functi~ class II, whereas in MILlU78, a slit majority of 
the patients were in ciass III. Within each study, the 
characteristics of the treatment groups were similar. 
Exerek duration. In both studies, exercise duration dur- 
ing the baseline phase was comparable in the mihimne and 
placebo groups. In MIL-1077, baseline xercise duration 
was 520 f 37 and 494 f 38 s in the placebo and mihinone 
groulw, respectively. In MIL1078, baseline exercise dura- 
tion was 545 f 30 and 588 f 30 s in the placebo and 
mihinone groups, respectively. 
In both studies, analysis of patients who completed the 
studies or reached an end point revealed clear trends toward 
improved exercise capacity in the mihinone proups (Fii. I). 
III MILlO77, exercise duration increased by 23 -C 34 s in the 
placebogroupandby87 f 31 sinthemilrinone8roup(p =
0.166). In MILIO78, exercise duration increased by 4 f 24 s 
in the placebo group and by 43 k 22 s in +he mihkone goup 
(p = 0.233). Analysis of the combined data for MILK?77 and 
MILlW8, reflectias 60 placebo-treated and 71 mihinone 
treated patients, demonstrated a 17 + 4% increase in exer- 
cise duration in the milrinone group as compared with a 3 * 
4% change in the phtcebo group (p = O&27). 
T 
0 Fhcebo 
30 n Milrinone 
ML-1077 MIL107a ML1077 a 1070 
;valw “006? . 36 0.202 43 60 0m 71 
Flga~ 1. Percent change in exercise duration in MRrlO77 aad 
MILl078 &ials of milrinoae and a converting enzyme inhibitor 
without and with, respectively, di&lis). Baseline xercise dutioa 
was similar in placebo- aad milriaoae-treated patients in both 
studies as described in the text. The data showa are an eod poiat 
~~sforall~~whocompktedthctrialsoareachedtheead 
point of need for cointervention or death. 
symptomsaudqMIityofufe. InMILItV7,nosigniknt 
eifects (p C 0.05) of mihinone therapy on symptoms of 
congestive heart failure or the quality of life global scores 
were detected. InMIL1078, exertional dyspnea and orthop- 
nea were significantly improved in the milrinone-treated 
patients, but there were no sbificant changes inthe quality 
of life global scores. 
Adverse wmts (Table 3). The most frequent adverse 
events in bth studies were dizziness and hypotension. I  
MIL-1077, patients inthe mihinone group experienced more 
hypotension and visual disturbances than did those in the 
TaWe3.NumberofPatientsWithdmw11FromtheStudyBecsuse 
of an AdverJe Event 
MILKi MILlo78 
EVUlt PkeboIbfhlnwplreeboMilrinwc 
FalpitaIion 
SVT 
VT 
syacope 
Diz%lncss 
Hypotension 
Hypelkllhll 
CHF 
MI 
Menut status 
visual distti 
TdsllWkat.4 
0 
0 
0 
0 
0 
0 
1 
0 
0 
0 
0 
0 
1 
3 
I 
I 
0 
0 
I 
0 
0 
1 
I 
I 
0 
9 
0 
0 
0 
0 
0 
0 
0 
0 
0 
0 
0 
0 
0 
I 
I 
3 
I 
I 
0 
0 
I 
0 
I 
0 
2 
9 
m+ pcrcentofpatiudsMatingpnrerrhytbmiacritwia*inMIL1077endMIL1078combined 
IWceL 1MlUltll 
(Z& 
Mikhle 
(n=106) due 
PIado Marhone 
(II = 81) (n-92) dllc 
WfW=Y 4 5 1.0 7 5 0.8 
lkpdtiwfwms I 11 < 0.01 6 IO 0.4 
LvT 4 1 8 3 0.6 OA 3 4 0 3 0.2 1.0 
qMinalMia~1.Ab~rrinTables1and3. 
phlC&OgrOUp.IOMIL1878,thChlCidWWOfdi8ZiWSSlUld 
headachewassi8ld8calltly~inthepljlrinollctreated 
mup. In the two studies taken together, adverse events 
CcIIultcd in the withbwal of 18 patients from the milrinone 
groups compared with only 1 placebo-treated patient. 
Ambplrtg--=MWhk--4)* 
AaalysisdthepooledHolterdatafromthetwostudies 
revealedthatatlweekoftherapy,therewasahigher 
incidenceofrepetitiveventricular~sinthenWnone- 
treated patients (11% vs. l%), but no dkences in any of 
the other mythmia criteria. At 1 month of therapy, 
theFHW!reIUI~hallydtheproalThythmia 
critekAnalysisdtheindividualstudiesreveaMsimilar 
patterns. 
cudionrdrrdeaths(Talde5).TheleweIefkWrcardio= 
vasadardeathsinMIL-1oT7andsixinMIG10?8.Therewas 
. 
cm B death in ML1077 (in a patient 
receivilqg placebo) and none ia MiLlu78. Wdiovascular 
deaths were equally distriited between placebo- and 
. . 
~patieatsinbothstudii.Thecewasao 
apparenttrendwith~tothemudeofdeath.IllMIL 
1078, the two patients who died of apparent arrhythmia h d 
beeawithdrawnfkommibimmetherapyfor2daysand2 
months, respectively. 
-on 
Theconclpsiormthatcanbedrawnframtheseenicacy 
studiesarelimitedbecauseoftheirearlytemktion.Nev- 
erthek,thetotalnumberofpatkatswlloreachedanend 
point in the two studies (140 patients) is substantial and 
allowssmeralobservetionsthat~yberelevaantothe 
futuredevelopnentaaduseoforallyactivedrqgsthatinhibit 
phosphodiestemse in patients with wngestive h art failure. 
‘LLbic5.caldhmkDeatbsillMIL1mmldMc1078 
ML477 MlLlO78 
Raccbo-plr#boldilrinaae 
- I 0 2 2 
G 
1 1 1 .o 
0 0 0 0 
ontd_ 0 I 9 1 
Td 2 2 3 3 
These studies report the only controlled data reikctiug the 
clinicaMicacyofomlmilrinoneusedincombinatioIlwith 
converting enzyme inhibitors, which are now a standard 
componeat of he medical therapy ofcongestive h art fail- 
ure. 
WeWtkIneachofthestudies,therewasa 
notable trend toward an increase in symptom-limited ex r- 
cise duration, the primary end point of both studies. On the 
basisofthepriortrialbyDiBiancoetal.(6),theseefficacy 
uialswerp:desig&todetecta60_sdi&renceiaexercise 
dumtion between the treatment and placebo groups. Be 
caU!Xonly+0%ofthepkUEdmlmberofpatieIltshad 
compked either trial at the trlne of study termination, 
statistical significance was not reached in the individual 
trials. However, given the simikity between the patient 
groups and overall study des@ of the two trials, we 
thought it just&d and certainly ofinterest to examine the 
combinedexercisedataofthetwotriels.Whenwecombined 
thedataofthetwotrials,wefoundanaveragc17~4% 
krease in exe&e capacity in the milrinone group, which is 
8igni6cantlymorethanthe3~496inuease i  the placebo 
group. Both the absdute (a0 s) and percent (17%) increases 
illexerciSedWatiollfromthefX&ilKddatafiDmMIL-l077 
aadMIL-1078aresimilarinmagnitudetotheincreasesin 
exercise duration (83 s [Ml) observed with milriaone in the 
study by DiBianco et al. (6). Thus, the results of these 
e#icacytrialsancomdstentwithtlleconcl~thatmilri- . 
exerckcapacityinpatientswithmoderate 
zgez*aMl thatthise&ctmayalso 
occur in @ien& treated with converting enzyme inhibks. 
ControMtrialsoftwo&ernewpositiveWropicagents, 
+oben&m (11) and oPC-8212 (12), have also shown an 
unpaovemcntin~capacityinpatientswith~ 
to severe coqestive heart failute treated with diuretic 
agents, digitalis and converting enzyme inhiitors. Taken 
m, these 0bsenMks suggest that despite optimal 
conventhmaltherapywithac0nveztingenzymehWitor,it 
ispossibleto~eexercisecapacityfurther.Because 
thesenewpositiveinotropicagents(mkinone,pimobe&n, 
OPC-8212)exertavarietyofpoe&iveinotropic,andinsome 
cases,vaxnWoractions,theexactmechaniibywhii 
theyimproveexerck capacityremaiostobedekXm&d 
DiBisncoetrl.(ti)olHervedthatmihiMmeand~s 
eachimprovedexercisecapaGtywhenusedalone,whereas 
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the combination f mihinone plus digitalis was no better than 
either drug alone. Comparison of both the absolute and 
percent incus in exercise duration in ML1077 and 
ML-1078 appears to reflect a similar pattern. The improve- 
ment in exercise capacity n MIL1077, which excluded 
digitalis, was greater than that in MILl078, which required 
concomitant digitalis therapy. These observations therefore 
further aise the possibility of an interaction f phosphodi- 
esterase inhibiting agents with digoxin. 
These studies detected little or no effect of milrinone on 
the symptoms of congestive heart fail= or quality of life. 
Mihhume signilicantly improved heart faihue symptoms 
only in IUIMtJ7d and had no siguilicant effect on quality of 
life in either study. The lack of a clearer beneficial ction on 
symptoms and quality of life may rellect he premature 
termination ofthe studies, resulting in inadequate statistical 
power and the high incidence af adverse events in milrinone- 
treated patients. 
Adverse &cts. In both studies, oral milrinone treatment 
was associated with an increase in adverse vents, the 
majority of which were categorized ashypotension, dixxi- 
ness or headache. The incidence of these events iu MI.,477 
andMILlO78was~~inthestudybyDiB~coet 
al. (6). The major difference between these fhcacy trials and 
the prior study of DiRiico et al. (6) was the prohibition of 
converting enzyme inhibitors (or other vasodilators) in the 
earlier study and their inclusion in the present trials. Our 
observations theretore suggest that he use of m&none with 
a converting enxyme inhibitor may cause more vasodilator- 
&ted adverse ffects than the use of milrinone alone and 
probably teflects the potent direct arterial nd venous dilator 
effects of mihinone (13). 
In view of the increased mortality rate in milrinone- 
tteated patients inthe PROMISE trial (7), the catdiovascular 
mortality in the present trials is of special importance. Roth 
the number of patients who died of cardiovascular causes 
andtheapparentmodesofdeathwetcsimilarinmilrinone- 
and placebo-treated patients in both trials. These trials were 
notpowerlulenoughtodetectasignilicatite#ectofmilri- 
none on survivak however, the lack of any trend suggests 
that over the time wurse of these studies, mihiwne did not 
exert an adverse e8ect on survival. This suggestion is 
consistent with the prospective subgroup analysis in the 
PROMISE trial (7), which found that the risk ratio of 
milrinone therapy was substautially inaeased (1.53) in pa- 
tients in functional class IV but not (1.03) in those in 
functionalclassIII.ThepatientsinMIL1~andMIL1078 
were almost exchtsively in l&tkmal classes II and III and 
were &ically stable before entetiug the trials and thus 
diBeted matkedly &om putients in the PROMISE trial, who 
wereinfunctionalclassIIIandIVaudwereoftenclinically 
unstable. 
TheusedoralmilrinoneiuthePROMISEtrial(10)was 
associatedwithasig&antincreaseinprourrhythmiade- 
tectedby24-hHoltermo&or@.InhlILl@77andbIIL 
10T8,theeRectsof&inonetherapyonventriculararrhyth- 
mia were less prominent. At 1 week oftberapy, there was a 
Signillcant increase in repetitive forms when the data from 
the two trials were canbined, but no significmt change ia 
any of the other mhythmia criteria At 1 month. the 
incidence ofproarrhytlunia w s comparable in the mihinone 
and placebo groups of the individual stud& as well as from 
thecombinedda&Inthesestudies,therewaslittleevidence 
of an association between a change in ventricular thytb- 
miss and apparent sudden death (or cardiovascular death of 
any cause). 
Of the patients in the n&inone treatment groups who 
died of a cardiovascular cause, only two were receiving 
milrinoneatthetimeddeath.Theotherthreebadbeen 
withdrawnfrommilrinoaetherepy2days(one~)and2 
months (two patients) before they died. Of the eight patients 
receivingmilriuone whohadanincreaseinthelongestrunof 
the ventricular tachycardia at 1 week, one patient subse- 
quently died 2 months after discontinuing active drug. Nei- 
ther of the hvo patients who died while tiving mihiwne 
showed any mhythmia criterion at 1 week or 1 month of 
Holter monitoring. Thus, milrinone had only minor etTects 
onproarrhythmia,andaproanhythmice%ct,whenit 
occuned,didnotappeartohavecontriitedtoca&was- 
cular mortality. 
Cenclnslons. Although there have been ~~--wMxz~ in the 
therapy of wngestive heart failure over the last several 
years, manypatientscontinuetohave&~~~symptoms 
of congestive h art faihue despite optimal medical therapy. 
The development of new agents and new therapeutic strat- 
egies therefore is mandatory. New drugs will need to be 
discovered and integrated with existing thempies. The po- 
tential role of phosphodiesterase inhibiting agents or anrgS 
that incorporate phosphodiesterase inhibition in their utech- 
anism of action remains unclear. Although the PROMISE 
tl%lsbowedthat0ral-increasedthemortalityrate 
inpatientswithseveteheartKhtre,theeRbctofph~ 
di steraseinhibitorssuchas~~on~~~~in~ 
with stable, mild or moderate heart failure remains un- 
known.TheresultsoftheseeUlcacytrials,takenWgether 
withtheencour&greportsofotherneWerphosphodiester- 
ase inhibitors uch as pimobe&n (11) and Opt-8212 (12). 
signi@ that oral agents with phosphodiesteutse inhibiting 
activity may still have a role in the treatment of congestive 
heart faihlre. 
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